Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $326.25 Average PT from Brokerages

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have been assigned a consensus rating of “Moderate Buy” from the eleven analysts that are currently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $326.25.

Several research firms recently weighed in on KRYS. HC Wainwright reiterated a “buy” rating and issued a $310.00 target price (up from $240.00) on shares of Krystal Biotech in a report on Friday, January 9th. Citigroup boosted their price objective on Krystal Biotech from $336.00 to $371.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Zacks Research lowered Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 5th. Weiss Ratings cut shares of Krystal Biotech from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, March 25th. Finally, Jefferies Financial Group lifted their price objective on shares of Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a report on Tuesday, February 17th.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $263.21, for a total transaction of $6,580,250.00. Following the transaction, the insider owned 1,403,155 shares of the company’s stock, valued at approximately $369,324,427.55. This trade represents a 1.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Daniel Janney sold 37,895 shares of Krystal Biotech stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $266.88, for a total transaction of $10,113,417.60. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 129,164 shares of company stock valued at $34,538,578. Corporate insiders own 13.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Soleus Capital Management L.P. grew its position in shares of Krystal Biotech by 108.9% in the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after purchasing an additional 481,200 shares during the period. Braidwell LP grew its stake in Krystal Biotech by 81.6% during the 2nd quarter. Braidwell LP now owns 727,811 shares of the company’s stock valued at $100,045,000 after purchasing an additional 327,067 shares in the last quarter. Norges Bank bought a new stake in shares of Krystal Biotech in the fourth quarter worth $70,159,000. William Blair Investment Management LLC increased its holdings in shares of Krystal Biotech by 152.1% in the 4th quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock valued at $92,783,000 after acquiring an additional 227,038 shares during the last quarter. Finally, Janus Henderson Group PLC increased its holdings in shares of Krystal Biotech by 2,078.9% during the fourth quarter. Janus Henderson Group PLC now owns 219,440 shares of the company’s stock valued at $54,147,000 after purchasing an additional 209,369 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Stock Up 4.6%

NASDAQ:KRYS opened at $258.32 on Friday. Krystal Biotech has a 52 week low of $122.80 and a 52 week high of $298.30. The stock’s fifty day moving average is $266.25 and its two-hundred day moving average is $231.99. The company has a market capitalization of $7.55 billion, a P/E ratio of 37.71 and a beta of 0.49.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Tuesday, February 17th. The company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The firm had revenue of $107.11 million during the quarter, compared to the consensus estimate of $105.30 million. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%. Sell-side analysts anticipate that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.